WallStSmart

Johnson & Johnson (JNJ)vsZhongchao Inc (ZCMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 860814% more annual revenue ($97.93B vs $11.38M). JNJ leads profitability with a 21.5% profit margin vs -55.5%. JNJ earns a higher WallStSmart Score of 57/100 (C).

JNJ

Buy

57

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 4.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64

ZCMD

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 8.0
Piotroski: 1/9Altman Z: 7.52

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$615.36B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
21.5%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
28.6%8/10

Strong operational efficiency at 28.6%

Free Cash FlowQuality
$3.39B8/10

Generating 3.4B in free cash flow

ZCMD3 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.5210/10

Safe zone — low bankruptcy risk

Areas to Watch

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
29.1x4/10

Moderate valuation

PEG RatioValuation
4.142/10

Expensive relative to growth rate

EPS GrowthGrowth
-1.0%2/10

Earnings declined 1.0%

ZCMD4 concerns · Avg: 2.5/10
Market CapQuality
$1.85M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-37.3%2/10

ROE of -37.3% — below average capital efficiency

Revenue GrowthGrowth
-23.2%2/10

Revenue declined 23.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.

Bull Case : ZCMD

The strongest argument for ZCMD centers on Price/Book, Debt/Equity, Altman Z-Score.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Bear Case : ZCMD

The primary concerns for ZCMD are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

JNJ profiles as a mature stock while ZCMD is a turnaround play — different risk/reward profiles.

JNJ is growing revenue faster at 6.6% — sustainability is the question.

JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JNJ scores higher overall (57/100 vs 29/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Zhongchao Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · China

Zhongchao Inc. provides health care information, education and training services in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.

Visit Website →

Want to dig deeper into these stocks?